308 related articles for article (PubMed ID: 8656777)
21. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.
García-Lerma JG; Nidtha S; Heneine W
J Infect Dis; 2001 Aug; 184(4):507-10. PubMed ID: 11471110
[TBL] [Abstract][Full Text] [Related]
22. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
Domaoal RA; Demeter LM
Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
[TBL] [Abstract][Full Text] [Related]
23. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
Ross L; Johnson M; Graham N; Shaefer M; St Clair M
J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
[TBL] [Abstract][Full Text] [Related]
24. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.
Das K; Lewi PJ; Hughes SH; Arnold E
Prog Biophys Mol Biol; 2005 Jun; 88(2):209-31. PubMed ID: 15572156
[TBL] [Abstract][Full Text] [Related]
25. Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors.
Jones LH; Allan G; Corbau R; Hay D; Middleton DS; Mowbray CE; Newman SD; Perros M; Randall A; Vuong H; Webster R; Westby M; Williams D
ChemMedChem; 2008 Nov; 3(11):1756-62. PubMed ID: 18855969
[TBL] [Abstract][Full Text] [Related]
26. Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1.
Turner D; Brenner B; Wainberg MA
J Antimicrob Chemother; 2004 Jan; 53(1):53-7. PubMed ID: 14645322
[TBL] [Abstract][Full Text] [Related]
27. Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity.
Campiani G; Nacci V; Fiorini I; De Filippis MP; Garofalo A; Greco G; Novellino E; Altamura S; Di Renzo L
J Med Chem; 1996 Jul; 39(14):2672-80. PubMed ID: 8709096
[TBL] [Abstract][Full Text] [Related]
28. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
[TBL] [Abstract][Full Text] [Related]
29. New type of HIV drug.
Treat Rev; 1995 Nov; (no 20):4. PubMed ID: 11363022
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
31. The effect of NNRTIs on HIV reverse transcriptase dimerization.
Tachedjian G; Goff SP
Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
[TBL] [Abstract][Full Text] [Related]
32. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.
Balzarini J; Weeger M; Camarasa MJ; De Clercq E; Uberla K
Biochem Biophys Res Commun; 1995 Jun; 211(3):850-6. PubMed ID: 7541200
[TBL] [Abstract][Full Text] [Related]
33. Nucleoside reverse transcriptase inhibitors and HIV mutagenesis.
Jewell NA; Chen R; Raices R; Mansky LM
J Antimicrob Chemother; 2003 Oct; 52(4):547-50. PubMed ID: 12951341
[No Abstract] [Full Text] [Related]
34. Therapy other than reverse transcriptase inhibitors for HIV infection.
Kaplan JC; Hirsch MS
Clin Lab Med; 1994 Jun; 14(2):367-91. PubMed ID: 7523020
[TBL] [Abstract][Full Text] [Related]
35. New strategies for treating AIDS.
Sandstrom PA; Folks TM
Bioessays; 1996 May; 18(5):343-6. PubMed ID: 8639156
[TBL] [Abstract][Full Text] [Related]
36. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
Balzarini J; Pelemans H; Aquaro S; Perno CF; Witvrouw M; Schols D; De Clercq E; Karlsson A
Mol Pharmacol; 1996 Aug; 50(2):394-401. PubMed ID: 8700148
[TBL] [Abstract][Full Text] [Related]
37. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus.
Ichimura H; Levy JA
Virology; 1995 Aug; 211(2):554-60. PubMed ID: 7544050
[TBL] [Abstract][Full Text] [Related]
38. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
[TBL] [Abstract][Full Text] [Related]
39. Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.
Rezende LF; Prasad VR
Int J Biochem Cell Biol; 2004 Sep; 36(9):1716-34. PubMed ID: 15183340
[TBL] [Abstract][Full Text] [Related]
40. Novel naphthalenedisulfonic acid anti-HIV-1 agents. Synthesis and activity against reverse transcriptase, virus replication and syncytia formation.
Mohan P; Singh R; Baba M
Drug Des Discov; 1991 Nov; 8(1):69-82. PubMed ID: 1725723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
